Coya Therapeutics expands exclusive COYA 301 rights agreement with ARScience

Coya Therapeutics announced expansion of its exclusive worldwide rights for the development and commercialization of COYA 301, the company’s low-dose IL-2 subcutaneous administration product candidate. Under the expanded terms of the agreement with ARScience Biotherapeutics, Coya has been granted the rights to develop and commercialize COYA 301 as a monotherapy for the treatment of multiple autoimmune diseases. These additional rights expand on the rights provided in the original license which allowed Coya to develop and commercialize the product candidate as monotherapy for a number of neurodegenerative conditions and as a combination Treg-based therapy across multiple therapeutic areas.